Skip to main content
. Author manuscript; available in PMC: 2022 Jan 17.
Published in final edited form as: Leukemia. 2021 Jul 17;35(10):2854–2861. doi: 10.1038/s41375-021-01342-x

Figure 4: Cumulative incidence of atrial fibrillation, hypertension, and infection, by treatment group.

Figure 4:

The cumulative incidence of grade 3 or higher atrial fibrillation occurring in 176 patients treated with bendamustine plus rituximab (BR) and 361 patients treated with ibrutinib regimens (IBR) is depicted (a), all grades of atrial fibrillation (b), grade 3 or higher hypertension (c), all grades of hypertension (d), grade 3 or higher infection (e), all grades of infection (f).